Render Target: SSR
Render Timestamp: 2024-11-14T23:03:59.479Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:53:37.194
Product last modified at: 2024-10-29T13:45:08.705Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

S100A4 (D9F9D) Rabbit mAb #13018

Filter:
  • WB
  • IP
  • IHC

    Supporting Data

    REACTIVITY H M
    SENSITIVITY Endogenous
    MW (kDa) 12
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    For a carrier free (BSA and azide free) version of this product see product #48842.

    Protocol

    Specificity / Sensitivity

    S100A4 (D9F9D) Rabbit mAb recognizes endogenous levels of total S100A4 protein.

    Species Reactivity:

    Human, Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala54 of human S100A4 protein.

    Background

    Despite their relatively small size (8-12 kDa) and uncomplicated architecture, S100 proteins regulate a variety of cellular processes, such as cell growth and motility, cell cycle progression, transcription, and differentiation. To date, 25 members have been identified, including S100A1-S100A18, trichohyalin, filaggrin, repetin, S100P, and S100Z, making it the largest group in the EF-hand, calcium-binding protein family. Interestingly, 14 S100 genes are clustered on human chromosome 1q21, a region of genomic instability. Research studies have demonstrated that significant correlation exists between aberrant S100 protein expression and cancer progression. S100 proteins primarily mediate immune responses in various tissue types but are also involved in neuronal development (1-4).

    Each S100 monomer bears two EF-hand motifs and can bind up to two molecules of calcium (or other divalent cation in some instances). Structural evidence shows that S100 proteins form antiparallel homo- or heterodimers that coordinate binding partner proximity in a calcium-dependent (and sometimes calcium-independent) manner. Although structurally and functionally similar, individual members show restricted tissue distribution, are localized in specific cellular compartments, and display unique protein binding partners, which suggests that each plays a specific role in various signaling pathways. In addition to an intracellular role, some S100 proteins have been shown to act as receptors for extracellular ligands or are secreted and exhibit cytokine-like activities (1-4).

    Research studies have shown that S100A4 is overexpressed in highly metastatic cancers, which makes it useful as a marker of tumor progression (5,6) and may serve as a prognostic factor in several cancer types (7-10). S100A4 exerts its function via direct interaction with a number of proteins including P53, P63, nonmuscle myosin IIA, α6β4 integrin, and liprin b1 (11-15). S100A4 is present in the nucleus, cytoplasm and extracellular space. Intracellular and extracellular S100A4 both promote cell migration via interaction with different proteins. Researchers have recently discovered that S100A4 also functions as a neuroprotectant in the peripheral nervous system (16,17).
    1. Heizmann, C.W. et al. (2002) Front Biosci 7, d1356-68.
    2. Donato, R. (2003) Microsc Res Tech 60, 540-51.
    3. Marenholz, I. et al. (2004) Biochem Biophys Res Commun 322, 1111-22.
    4. Santamaria-Kisiel, L. et al. (2006) Biochem J 396, 201-14.
    5. Ismail, N.I. et al. (2008) Cancer Cell Int 8, 12.
    6. Ismail, T.M. et al. (2010) J Biol Chem 285, 914-22.
    7. Rudland, P.S. et al. (2000) Cancer Res 60, 1595-603.
    8. Huang, L.Y. et al. (2011) World J Gastroenterol 17, 69-78.
    9. Wang, L.J. et al. (2012) Appl Immunohistochem Mol Morphol 20, 71-6.
    10. Kang, Y.G. et al. (2012) J Surg Oncol 105, 119-24.
    11. Kriajevska, M.V. et al. (1994) J Biol Chem 269, 19679-82.
    12. Takenaga, K. et al. (1994) J Cell Biol 124, 757-68.
    13. Kriajevska, M. et al. (2002) J Biol Chem 277, 5229-35.
    14. Kim, T.H. et al. (2009) Mol Cancer Res 7, 1605-12.
    15. van Dieck, J. et al. (2010) Oncogene 29, 2024-35.
    16. Dmytriyeva, O. et al. (2012) Nat Commun 3, 1197.
    17. Moldovan, M. et al. (2013) Mol Med 19, 43-53.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.